[Form 4] CytomX Therapeutics, Inc. Insider Trading Activity
Rhea-AI Filing Summary
CytomX Therapeutics insider grant to Chief Medical Officer
Yu-Waye Chu, Chief Medical Officer of CytomX Therapeutics, acquired equity awards on 09/26/2025 consisting of a stock option to purchase 87,500 shares of common stock at an exercise price of $2.90 and 43,750 Performance Stock Units (PSUs), each PSU representing one contingent share. The option vests monthly at 1/48th beginning on the Vesting Commencement Date of 09/26/2025 and becomes fully vested on the fourth anniversary if the reporting person remains in service. The PSUs vest in three tranches, with 1/3 vesting upon achievement of each of three specified clinical milestones, subject to continued service. All reported holdings are direct.
Positive
- None.
Negative
- None.
Insights
TL;DR: A routine executive equity grant: an 87,500-share option at $2.90 plus 43,750 PSUs aligns CMO incentives with clinical progress.
This equity grant combines time-based option vesting and milestone-based PSUs, linking compensation to both retention and specific clinical outcomes. The option's 1/48th monthly vesting over four years is standard for executive awards and supports retention. The PSUs vest only upon achievement of three clinical milestones, creating direct linkage between pay and program progress. Investors should note the exact quantities and exercise price disclosed; the transaction is a non-derivative acquisition reported as direct ownership.
TL;DR: Grant structure reflects best practices by mixing time-based and milestone-based equity to align executive incentives with company goals.
The award packaging—time-vested options plus milestone PSUs—is a governance approach that balances retention with performance orientation, particularly appropriate for a clinical-stage biotech. Vesting conditions are explicit: monthly pro rata option vesting over four years and PSU vesting tied to three clinical milestones with service conditions. The Form 4 filing properly discloses the transaction details and direct beneficial ownership following the grant.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 87,500 | $0.00 | -- |
| Grant/Award | Performance Stock Units (PSUs) | 43,750 | $0.00 | -- |
Footnotes (1)
- 1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.
